Swedish Orphan Biovitrum (Sobi) and Innate Pharma have formed a strategic partnership to initiate the TELLOMAK-3 Phase 3 trial for lacutamab, targeting cutaneous T-cell lymphoma (CTCL), including Sézary syndrome. This trial is a key step toward accelerated approval and eventual full approval of lacutamab, a novel antibody treatment. Sobi will gain exclusive global commercialization rights upon approval and may assume full development rights after positive Phase 3 results. The deal includes upfront and milestone payments to Innate Pharma, supporting the advancement of this rare disease therapy globally.
Cardano (ADA) has gained about 17% in the past week, trading around $0.224 amid rising on-chain activity and major wallet accumulation. Decentralized exchange volumes on Cardano's network tripled in 48 hours, signaling increased engagement. Large hol...
Lockheed Martin received a Buy rating due to its record $230 billion backlog and strong demand for PAC-3 and THAAD missile defense systems. The company’s moderate valuation compared to peers and steady free cash flow yield of about 5.8% support the p...
Arthur Hayes, co-founder of BitMEX, purchased 244,406 UNI tokens for about $1.73 million amid Uniswap's expansion of its protocol-fee system that burns UNI tokens, reducing supply. This mechanism, active since late 2023, links fee collection to token...
Solana attracted $348 million in net real-world asset (RWA) flows over the past 30 days, boosting its total distributed RWA value to about $4.23 billion. This growth outpaced competitors like Ethereum and Stellar, driven by tokenized U.S. Treasury an...
A UK investor named Chris recovered bitcoin worth about $4.5 million after losing access for over 13 years due to the shutdown of the Britcoin/Intersango exchange. He initially bought bitcoin in 2011 for around £1,500 when prices were under $4 per co...
